Search

everythinglearnresearchcommunity

for

Search:↓

Belimumab effectively reduces disease activity in lupus patients, regardless of initial serologic status.

Nrf-2-modified stem cells from hair follicles significantly improve ulcerative colitis in rats.

Hydroxychloroquine may help delay skin damage in lupus patients.

Serial trichoscopy is more reliable than the modified hair pull test for tracking alopecia areata.

Absence of skin rash and low complement C3 levels increase the risk of lupus nephritis.

Machine learning can predict symptoms and quality of life in chronic skin disease patients using smartphone app data, and shows that app use varies with patient characteristics.

PRO-C22 can help diagnose and monitor the severity of hidradenitis suppurativa.

Higher disease activity in systemic lupus erythematosus is strongly linked to more internal organ damage.

Most patients with cutaneous dermatomyositis either improved or remained stable over 3.5 years.

Lower GPX4 mRNA levels are linked to higher disease activity and symptoms in lupus patients.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

The index to ring finger ratio may indicate disease severity in female ankylosing spondylitis patients, but not in males.

BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Trichoscopy is useful for diagnosing and monitoring systemic lupus erythematosus, with certain hair and scalp changes indicating more active disease.

Skin disease activity scores can help decide when skin symptoms no longer affect the quality of life in patients with mild dermatomyositis.

The document concludes that better tools are needed to measure skin disease severity in dermatomyositis and cutaneous lupus erythematosus, and introduces the DSSI and CLASI as reliable instruments.

The CLASI is useful but needs revision to accurately assess all cutaneous lupus erythematosus subtypes.

Tofacitinib may help treat severe hair loss, but more research is needed.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Corticosteroid treatment reduces inflammation and alters hair keratins in alopecia areata.

The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.

Belimumab effectively controls SLE disease activity and reduces steroid use.

Choosing the right tools is crucial for accurately measuring lupus activity and damage.

Hair changes may indicate disease activity in pemphigus patients.

CLASI is a valid tool for assessing skin activity and damage in lupus patients.

Hair loss in lupus patients indicates higher disease activity.

A new tool helps lupus patients and doctors better track symptoms and quality of life.

Hair chemicals don't cause SLE but may increase skin issues in those with SLE.

The MPV/PC ratio can help assess disease activity in alopecia areata.